Erratum: Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics (Brain (2014) 137 (2271-2286) DOI: 10.1093/brain/awu139);Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics

Brain

Volumn 137, Issue 8, 2014, Pages 2271-2286

  Vidaurre, Oscar G ^a   Haines, Jeffery D ^a   Katz Sand, Ilana ^b   Adula, Kadidia P ^a   Huynh, Jimmy L ^a   Mcgraw, Corey A ^c   Zhang, Fan ^a   Varghese, Merina ^a   Sotirchos, Elias ^d   Bhargava, Pavan ^d   Bandaru, Veera Venkata Ratnam ^d   Pasinetti, Giulio ^a   Zhang, Weijia ^a   Inglese, Matilde ^a   Calabresi, Peter A ^d   Wu, Gang ^a   Miller, Aaron E ^b   Haughey, Norman J ^d   Lublin, Fred D ^b   Casaccia, Patrizia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

axonal degeneration; demyelinating disease; lipid metabolism; mitochondria; neurodegenerative mechanism

Indexed keywords

CERAMIDE; GLUCOSE; GLUTAMIC ACID; IMMUNOGLOBULIN G; LACTIC ACID; LIPID;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; EMBRYO; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMPAIR NEURONAL BIOENERGETIC; LIPID ANALYSIS; LIPIDOMICS; MALE; MULTIPLE SCLEROSIS; NERVE CELL; NERVE CELL CULTURE; NERVOUS SYSTEM PARAMETERS; NEUROFILAMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STRESS; TRANSCRIPTOMICS;

AXONAL DEGENERATION; DEMYELINATING DISEASE; LIPID METABOLISM; MITOCHONDRIA; NEURODEGENERATIVE MECHANISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; CERAMIDES; COHORT STUDIES; ENERGY METABOLISM; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; YOUNG ADULT;

EID: 84904976158     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv090     Document Type: Erratum

References (67)

1. Alcazar A, Regidor I, Masjuan J, Salinas M, Alvarez-Cermeno JC. Axonal damage induced by cerebrospinal fluid from patients with relapsingremitting multiple sclerosis. J Neuroimmunol 2000; 104: 58-67.
2. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010; 11: R106.
3. Bandaru VV, Mielke MM, Sacktor N, McArthur JC, Grant I, Letendre S, et al. A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology 2013; 81: 1492-9.
4. Baratchi S, Kanwar RK, Kanwar JR. Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress. PLoS One 2011; 6: E15865.
5. Bielekova B, Komori M, Xu Q, Reich DS, Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One 2012; 7: E48370.
6. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-Acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
7. Bosca I, Magraner MJ, Coret F, Alvarez-Cermeno JC, Simo-Castello M, Villar LM, et al. The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. J Neuroimmunol 2010; 226: 143-6.
8. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883-97.
9. Bui T, Sequeira J, Wen TC, Sola A, Higashi Y, Kondoh H, et al. ZEB1 links p63 and p73 in a novel neuronal survival pathway rapidly induced in response to cortical ischemia. PLoS One 2009; 4: E4373.
10. Darios F, Lambeng N, Troadec JD, Michel PP, Ruberg M. Ceramide increases mitochondrial free calcium levels via caspase 8 and Bid: Role in initiation of cell death. J Neurochem 2003; 84: 643-54.
11. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing- remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121 (Pt 8): 1469-77.
12. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-89.
13. Echtay KS, Esteves TC, Pakay JL, Jekabsons MB, Lambert AJ, Portero- Otin M, et al. A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. EMBO J 2003; 22: 4103-10.
14. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009; 10: 48.
15. Falluel-Morel A, Aubert N, Vaudry D, Basille M, Fontaine M, Fournier A, et al. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 2004; 91: 1231-43.
16. Fischer MT, Wimmer I, Hoftberger R, Gerlach S, Haider L, Zrzavy T, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013; 136 (Pt 6): 1799-815.
17. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-Appearing white matter in multiple sclerosis. Brain 1998; 121 (Pt 1): 103-13.
18. Funfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012; 485: 517-21.
19. Guan XL, He X, Ong WY, Yeo WK, Shui G, Wenk MR. Non-targeted profiling of lipids during kainate-induced neuronal injury. FASEB J 2006; 20: 1152-61.
20. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004; 55: 257-67.
21. Hill JW, Poddar R, Thompson JF, Rosenberg GA, Yang Y. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 2012; 220: 277-90.
22. Huang JK, Ferrari CC, Monteiro De Castro G, Lafont D, Zhao C, Zaratin P, et al. Accelerated axonal loss following acute CNS demyelination in mice lacking protein tyrosine phosphatase receptor type Z. Am J Pathol 2012; 181: 1518-23.
23. Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, et al. Genetically driven target tissue overexpression of CD40: A novel mechanism in autoimmune disease. J Immunol 2012; 189: 3043-53.
24. Inglese M, Madelin G, Oesingmann N, Babb JS, Wu W, Stoeckel B, et al. Brain tissue sodium concentration in multiple sclerosis: A sodium imaging study at 3 tesla. Brain 2010; 133 (Pt 3): 847-57.
25. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006; 12: 138-43.
26. Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 2010; 13: 180-9.
27. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128 (Pt 11): 2705-12.
28. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012; 487: 443-8.
29. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 2009; 25: 1754-60.
30. Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998; 4: 12-5.
31. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-4.
32. Malekzadeh A, De Groot V, Beckerman H, van Oosten BW, Blankenstein MA, Teunissen C. Challenges in multi-plex and monoplex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods 2012; 56: 508-13.
33. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-5.
34. Marballi K, Quinones MP, Jimenez F, Escamilla MA, Raventos H, Soto- Bernardini MC, et al. In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation. J Mol Med (Berl) 2010; 88: 1133-41.
35. Matsumata M, Sakayori N, Maekawa M, Owada Y, Yoshikawa T, Osumi N. The effects of Fabp7 and Fabp5 on postnatal hippocampal neurogenesis in the mouse. Stem Cells 2012; 30: 1532-43.
36. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013; 8: E61835.
37. Mattiasson G, Shamloo M, Gido G, Mathi K, Tomasevic G, Yi S, et al. Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med 2003; 9: 1062-8.
38. Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, Woulfe J, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006; 439: 988-92.
39. Mielke MM, Bandaru VV, Haughey NJ, Xia J, Fried LP, Yasar S, et al. Serum ceramides increase the risk of Alzheimer disease: The Women's Health and Aging Study II. Neurology 2012; 79: 633-41.
40. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 2008; 18: 52-61.
41. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495-9.
42. Novgorodov SA, Gudz TI, Obeid LM. Long-chain ceramide is a potent inhibitor of the mitochondrial permeability transition pore. J Biol Chem 2008; 283: 24707-17.
43. Persson AK, Kim I, Zhao P, Estacion M, Black JA, Waxman SG. Sodium channels contribute to degeneration of dorsal root ganglion neurites induced by mitochondrial dysfunction in an in vitro model of axonal injury. J Neurosci 2013; 33: 19250-61.
44. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
45. Qiao H, Koya RC, Nakagawa K, Tanaka H, Fujita H, Takimoto M, et al. Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging 2005; 26: 849-55.
46. Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, et al. Interleukin-1beta causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol 2012; 71: 76-83.
47. Rossi S, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 2013; 20: 304-12.
48. Rossi S, Studer V, Motta C, Germani G, Macchiarulo G, Buttari F, et al. Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation 2014; 11: 32.
49. Sasaki M, Seo-Kiryu S, Kato R, Kita S, Kiyama H. A disintegrin and metalloprotease with thrombospondin type1 motifs (ADAMTS-1) and IL-1 receptor type 1 mRNAs are simultaneously induced in nerve injured motor neurons. Brain Res Mol Brain Res 2001; 89: 158-63.
50. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002; 122: 132-9.
51. Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, et al. Agedependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008; 11: 1024-34.
52. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-41.
53. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005; 128 (Pt 5): 1016-25.
54. Sullivan PG, Dube C, Dorenbos K, Steward O, Baram TZ. Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. Ann Neurol 2003; 53: 711-7.
55. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol 2007; 6: 677-86.
56. Tovar-Y-Romo LV, Tabatadze N, Bandaru VV, Megra B, Williams D, Kanmonge M, et al. Microvesicles released from astrocytes regulate the peripheral immune response to CNS inflammation. Abstracts of the 12th International Symposium on NeuroVirology. October 29-November 2, 2013. Washington, DC, USA. J Neurovirol November 2, 2013. Washington, DC, USA. J Neurovirol 2013; 19 (Suppl 1): S1-101.
57. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
58. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-91.
59. Tronel C, Rochefort GY, Arlicot N, Bodard S, Chalon S, Antier D. Oxidative stress is related to the deleterious effects of heme oxygenase- 1 in an in vivo neuroinflammatory rat model. Oxid Med Cell Longev 2013; 2013: 264935.
60. Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porque P, Villarrubia N, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-94.
61. Waschek JA. VIP and PACAP: Neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol 2013; 169: 512-23.
62. Waxman SG. Axonal conduction and injury in multiple sclerosis: The role of sodium channels. Nat Rev Neurosci 2006a; 7: 932-41.
63. Waxman SG. Ions, energy and axonal injury: Towards a molecular neurology of multiple sclerosis. Trends Mol Med 2006b; 12: 192-5.
64. Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008; 131 (Pt 11): 3092-102.
65. Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, et al. Tumor necrosis factor-Alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem 2009; 109: 1237-49.
66. Xiao BG, Zhang GX, Ma CG, Link H. The cerebrospinal fluid from patients with multiple sclerosis promotes neuronal and oligodendrocyte damage by delayed production of nitric oxide in vitro. J Neurol Sci 1996; 142: 114-20.
67. Yamanaka H, Obata K, Fukuoka T, Dai Y, Kobayashi K, Tokunaga A, et al. Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury. Neuroscience 2005; 132: 183-91.